Eric Richman

Eric Richman has held various positions in the healthcare industry since 2008. In that year, they became a Director at ADMA Biologics, Inc. In 2010, they added President & CEO and Director roles at PharmAthene, Inc. In 2016, they became a Venture Partner at Brace Pharma Capital and a Director and CEO at Tyrogenex. In 2017, they took on an Independent Director role at LabConnect. In 2018, they became an Independent Director at NovelStem International Corp. and a Director at ZyVersa Therapeutics Inc. In 2019, they became a Director at both NeuBase Therapeutics, Inc. and Horizon Infusions / InFuse Holdings, where they also served as Co-Founder. Eric currently holds the position of Director at Gain Therapeutics.

Eric Richman attended CUNY Medical School Sophie Davis School of Biomedical Education from 1980 to 1985, where they earned a BS in Biomedical Science. Eric then attended Thunderbird School of Global Management from 1986 to 1987, where they earned an MBA in Finance and International Marketing.